Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
Makaleler > Tam Makale · 2025
Yazarlar: Frederick J Raal, Vimal Mehta, Latife Meral KAYIKÇIOĞLU, Dirk Blom, Preeti Gupta, Avishay Elis, Traci Turner, Chris Daniels, Jeffrey Vest, Tracy Mitchell, Kate Caldwell, El Mustapha Bahassi, David Kallend, Evan A Stein
The Lancet Diabetes & Endocrinology, Uluslararası, Wos, 2025, cilt 13, ss 178-187